Ambrosia Biosciences

Biotech & Life Sciences · Boulder, United States · Founded 2020

Small molecule therapies for obesity and metabolic disorders, delivered orally MoreLess

Ambrosia Biosciences Inc. is a drug discovery company focused on developing orally delivered, small molecule-based therapies aimed at treating obesity and other metabolic disorders. The company operates in the biotechnology sector, primarily targeting healthcare providers and patients dealing with metabolic health issues. Ambrosia Biosciences collaborates with seasoned biotech investors to leverage their expertise and drive forward its drug discovery programs. The business model revolves around the research, development, and eventual commercialization of these therapeutic solutions. Revenue is generated through partnerships, licensing agreements, and future sales of approved therapies.

Keywords: drug discovery, small molecule therapies, obesity treatment, metabolic disorders, biotechnology, healthcare, investors, oral delivery, therapeutic solutions, commercialization.

Valuation $100–500M

Headcount <100

Total funding $100–500M

Unlock exact values

Company overview

Ambrosia Biosciences company information

The essential company record, classifications and operating signals in one place.

Status: Operational
Founded: 2020
Headquarters: Boulder, United States
Employees: 36
Open positions: 1
Dealroom signal: 73.5

Website ↗LinkedIn ↗

client focusb2bsub industryPharmaceuticalsub industryBioTechnologybusiness modelManufacturingindustryHealthsectorBiotechnologysectorDrug DevelopmentsectorWeight ManagementsectorMetabolismsectorBiotech and PharmasectorSmall MoleculessectorDT and LSsectorscience-based

Valuation & funding

Ambrosia Biosciences funding history

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES BOther financing	Mar 2026	$100M	$400M	Janus Henderson Investors · Blue Owl Capital · BVF Partners · Boulder Ventures	↗
SERIES AOther financing	Dec 2024	$9M	$80M	Boulder Ventures · Merck & Co. · BVF Partners	↗
SERIES AOther financing	Aug 2024	$16M	$64M	BVF Partners · Boulder Ventures	↗

Showing 3 recorded eventsUnlock the complete deal history →

Growth signals

Ambrosia Biosciences website traffic

Latest recorded traffic for Ambrosia Biosciences is 2.4K monthly website visits, down 7.7% over the last three months. Ambrosia Biosciences's team grew 2.9% over the past year.

Latest monthly visits2.4K 3-month web change-7.7% 1-year team growth+2.9%

Monthly website visits23 observations · Aug 2024–Jul 2026

Hover or focus a point to see its exact monthly valueCompare with peers →

Hiring

Open positions at Ambrosia Biosciences

Current openings linked to this company in Dealroom.

Scientist, Process ChemistryBoulder, CO · Other · Aug 11, 2026

1 distinct opening shownExplore hiring signals →

Comparisons

Ambrosia Biosciences compared with similar companies

Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
MEMetseraMetsera is a clinical-stage biopharmaceutical company dedicated to leading the next generation of medicines and solutions for obesity and metabolic diseases	New York City, United States	Acquired	68	$505M	$4.9B
PRProLynxExtending medicine impact with ultra-long-acting therapies	Brentwood, United States	Operational
ZPZealand PharmaDiscovery, design and development of innovative peptide-based medicines	Søborg, Denmark	Operational
VBVerdiva BioOral therapies for obesity and cardiometabolic disorders	London, United Kingdom	Operational
RTRaziel TherapeuticsRaziel Therapeutics is a clinical-stage pharmaceutical company developing a proprietary drug for targeted fat reduction	Jerusalem, Israel	Operational
ATAlveus TherapeuticsNext-generation obesity and metabolic disease therapies	Philadelphia, United States	Operational
KTKailera TherapeuticsA clinical-stage biopharma company advancing a diverse therapeutic pipeline aimed at delivering innovative treatments for obesity and related conditions	Waltham, United States	Operational
ATAmbagon TherapeuticsBiotechnology company developing small molecule drugs that target previously undruggable proteins for cancer treatment	Eindhoven, Netherlands	Operational

Showing 8 of the closest matchesCompare every metric →

Talent graph

Ambrosia Biosciences's talent

Book a demo to see the people

Team profiled 4 named & role-tagged

Founders /100 quality score

Key operators 2 quality /100

Potential founders likely future founders

Startup mafia alumni-founded startups

Talent movements in · out past 12 months

Source: Dealroom Talent Intelligence.

Investors

8 investors on Ambrosia Biosciences's cap table

Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.

Series A 8 investors entered at this stage

BVF Partners

Boulder Ventures

Merck & Co.

Blue Owl Capital

Redmile Group

Deep Track Capital

Janus Henderson Investors

Samsara BioCapital

Global footprint

Where Ambrosia Biosciences has talent and traffic

Workforce by country

1 countries with
team presence

🇺🇸 United States100%

1 country shown

In the news

Latest news about Ambrosia Biosciences

Recent press, funding announcements, and product moves mentioning Ambrosia Biosciences — open to read from the original sources.

See all news

Market sentiment

What the market is saying about Ambrosia Biosciences

An AI-synthesized read of the highest-engagement posts about Ambrosia Biosciences on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Ambrosia Biosciences’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Request a free trial

Takes under a minute. Already use Dealroom? Log in.